SCHEMBL295126

SCHEMBL295126

C[C@H](N)C(=O)Oc1ccc2ccccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RECQL P46063 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2A6 P11509 1/20 0.46
PPARG P37231 2/20 0.45
PPARA Q07869 2/20 0.45
EPHX1 P07099 2/20 0.45
PTPN7 P35236 1/20 0.45
MMP1 P03956 2/20 0.44
MMP12 P39900 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8906700 1.00 KMT2A (0.53) KMT2AMEN1MAPTTDP1KDM4E
Hydrochloric Acid SCHEMBL21633899 0.98 KMT2A (0.51) KMT2AMEN1MAPTTDP1KDM4E
Hydrochloric Acid SCHEMBL21633900 0.98 KMT2A (0.51) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL31323054 0.87 KMT2A (0.50) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL31322986 0.86 ELANE (0.57) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL11996303 0.86 ELANE (0.57) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL10325206 0.84 KMT2A (0.54) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL18256 0.84 KMT2A (0.54) KMT2AMEN1MAPTTDP1KDM4E
SCHEMBL6663601 0.83 KMT2A (0.53) KMT2AMEN1MAPTTDP1KDM4E
Hydrochloric Acid SCHEMBL7736403 0.83 KMT2A (0.53) KMT2AMEN1MAPTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024140670-A1 CONJUGATE AND USES THEREOF FULL-LIFE TECHNOLOGIES HK LIMITED (CN) 2024-07-04 WO claimed
US-20240174715-A1 PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS INDI MOLECULAR, INC. 2024-05-30 US claimed
US-11919972-B2 Peptide libraries with non-canonical amino acids REGENERON PHARMACEUTICALS, INC. (US) 2024-03-05 US claimed
WO-2022212698-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2022-10-06 WO claimed
EP-3810169-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BicycleTX Limited (GB) 2021-04-28 EP claimed
WO-2019243832-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 BICYCLETX LIMITED (GB) 2019-12-26 WO claimed
US-20180085479-A1 CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE J. STEFAN INSTITUTE (SI) 2018-03-29 US claimed
US-20140309273-A1 COMPOUNDS AND METHODS OF TREATING OBESITY YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-10-16 US claimed
US-20140227175-A1 CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE J. STEFAN INSTITUTE (SI) 2014-08-14 US claimed
EP-2723387-A1 CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE J. Stefan Institute (SI) 2014-04-30 EP claimed
US-20050164950-A1 Orally administered small peptides synergize statin activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-07-28 US claimed
WO-2005016280-A2 ORALLY ADMINISTERED SMALL PEPTIDES SYNERGIZE STATIN ACTIVITY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-02-24 WO claimed
US-20040254120-A1 Orally administered small peptides synergize statin activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-12-16 US claimed
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same NOVASPIN BIOTECH GMBH (DE) 2003-06-19 US claimed
WO-2002100885-A2 A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME NOVASPIN BIOTECH GMBH (DE) 2002-12-19 WO claimed
US-6232305-B1 ANTICANCER AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS NAEJA PHARMACEUTICAL INC. (CA) 2001-05-15 US claimed
EP-0961779-A1 SUBSTITUTED AMINO BICYCLIC-$g(b)-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (CA) 1999-12-08 EP claimed
CN-1234735-A Method for treating skin pigmentation JOHNSON & JOHNSON CONSUMER (US) 1999-11-10 CN claimed
WO-1998032766-A1 SUBSTITUTED AMINO BICYCLIC-β-LACTAM PENAM AND CEPHAM DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS SYNPHAR LABORATORIES INC. (US) 1998-07-30 WO claimed
CN-1156964-A Novel Peptides MERCK & CO INC (US) 1997-08-13 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309273-A1 COMPOUNDS AND METHODS OF TREATING OBESITY FABP4, LIPC, GPR119 KMT2A 1751/4885MEN1 4525/4885MAPT 1065/4885
US-20240174715-A1 PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS ARGLU1, NGLY1, VIP KMT2A 3792/4885MEN1 296/4885MAPT 4023/4885
US-20140227175-A1 CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE CTSB, CTSV, CTSE KMT2A 3762/4885MEN1 2970/4885MAPT 3277/4885
US-11919972-B2 Peptide libraries with non-canonical amino acids ARGLU1, NGLY1, VIP KMT2A 3792/4885MEN1 296/4885MAPT 4023/4885
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same SSTR5, SSTR3, SCTR KMT2A 4510/4885MEN1 629/4885MAPT 2988/4885
US-20180085479-A1 CATHEPSIN-BINDING COMPOUNDS BOUND TO A CARRIER AND THEIR DIAGNOSTIC USE CTSB, CTSV, CTSE KMT2A 3762/4885MEN1 2970/4885MAPT 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.